Senior Division Manager (South Central Region)

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

A Bachelor's degree is required, with an advanced degree being preferred. Candidates must possess at least 10 years of biotech/pharma sales experience, including a minimum of 3 years in a sales leadership role, and prior cross-functional experience is preferred. A proven track record in hematology/oncology and/or cell therapy markets is essential, along with inspirational leadership, clear communication, and advanced coaching and team development skills. An innovative and strategic mindset, with experience in building, coaching, and implementing actionable account plans, is also required. The role necessitates living within the assigned territory, which covers MS, AL, LA, AL, TX, MO, KS, CO, UT, AZ, NM, and requires at least 50% travel.

Responsibilities

The Senior Division Manager will build, lead, and inspire a team of seven sales professionals for the launch and expansion of anitocabtagene autoleucel. Responsibilities include developing and executing sales strategies, building and managing a high-performing team, and driving adoption of innovative therapies. This involves attracting, retaining, and developing top talent, onboarding and training the team to exceed launch expectations, and leading the team to meet and exceed sales and performance goals. The role also includes analyzing market trends and competitive activity, developing and implementing divisional sales plans, engaging with key customers to build relationships and advocacy, collaborating with partner Kite Pharma and field stakeholders, and attending/leading commercial activities at scientific meetings. Ensuring compliance with all regulatory and legal requirements is also a key responsibility.

Skills

Sales Strategy

Team Leadership

CAR T

Biotechnology

Cell Therapy

Sales Management

Launch Strategy

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free